Business Context and Reporting Period
This Form 8-K was filed by Hancock Jaffe Laboratories, Inc. on March 12, 2019. The company is a Delaware corporation developing medical devices, specifically the VenoValve for chronic venous insufficiency and the CoreoGraft for coronary artery bypass graft surgeries. The filing primarily reports on a private placement offering of common stock.
Key Financial Metrics
- Capital Raised: $2,714,000 in gross proceeds from the sale of 2,360,051 shares of common stock at $1.15 per share.
- Shareholders' Equity: Approximately $3.3 million as of the filing date, following the capital raise.
- Placement Agent Fees: 10% of gross proceeds in cash, plus reimbursement of up to $25,000 in accountable expenses, and a non-accountable expense of 1% of proceeds.
- Warrant Issuance: Placement agent received a warrant for 8% of the total shares sold (approx. 188,804 shares) with a $1.50 exercise price, exercisable for five years.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or cash flow figures for a reporting period.
Material Changes
The primary material change is the increase in shareholders' equity to approximately $3.3 million due to the private placement. The company has also advanced its clinical development timeline, having implanted the first VenoValve in a patient in Bogota, Colombia, in February 2019.
Outlook, Management Commentary, and Risks
- Use of Proceeds: Funds will be used to fund the continued development of VenoValve and CoreoGraft, as well as for working capital and general corporate purposes.
- Product Pipeline:
- VenoValve: First-in-human study enrollment is ongoing with follow-up assessments scheduled at 14, 30, 60, and 90 days.
- CoreoGraft: Pre-clinical feasibility study is underway at the Texas Heart Institute, with results expected in June 2019.
- Risks: The filing includes a cautionary note regarding forward-looking statements. Actual results may differ due to risks in clinical development, regulatory approvals, and market conditions. The company undertakes no obligation to update these statements.
Investor Verification Checklist
- Verify the effectiveness of the registration statement for the resale of shares, which the company agreed to file by March 31, 2019.
- Monitor the enrollment progress and preliminary data from the VenoValve first-in-human study.
- Track the release of pre-clinical feasibility results for the CoreoGraft, expected in June 2019.
- Confirm the dilution impact of the 8% warrant issued to the placement agent.
- Review the company's cash burn rate to assess if the $3.3 million equity position is sufficient to reach the next funding milestone.